Manufacture is carried out using the most advanced and cutting-edge technology in the market, as is the case of the single-use technology. Likewise, once the product enters the commercialization phase, mAbxience carries out a clinical follow-up through pharmacovigilance programs that allow the detection of late toxicities, a typical phenomenon of any biotechnological drug regardless of whether or not it is biosimilar.